Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

CXCL12 protein can inhibit metastasis of colon and melanoma cancers

Researchers at the Medical College of Wisconsin have shown that a protein can inhibit metastasis of colon and melanoma cancers. The findings are published in the October 10, 2011 issue of Proceedings of the National Academy of Sciences.

11 Oct 2011

ICREA researcher has set up spin-off Supragen at IRB Barcelona

Roger Gomis, ICREA researcher at the Institute of Research in Biomedicine (IRB Barcelona) has set up the spin-off Supragen. With the support of IRB Barcelona and the Instituci- Catalana de Recerca i Estudis Avan-ats (ICREA), this initiative is the second biotech company to emerge from the institute since June and the third since this centre was set up towards the end of 2005.

4 Oct 2011

CSHL publishes 'The Mammary Gland as an Experimental Model' book

Studies of mammary gland biology are essential in the fight against breast cancer. Moreover, the mammary gland represents an excellent model system for investigation of physiological and pathological processes that occur throughout the body.

4 Oct 2011

MR-guided focused ultrasound may effectively control essential tremor

In a presentation at the Congress of Neurological Surgeons today, University of Virginia neurosurgeon W. Jeffrey Elias, MD reported that preliminary results of a pilot clinical trial indicate that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor (ET), a common neurological condition that affects 10 million Americans.

4 Oct 2011

Researchers identify specific molecule that alters how breast cancer cells move

Researchers from the University of Michigan Comprehensive Cancer Center have identified a specific molecule that alters how breast cancer cells move. This affects the cells' ability to spread or metastasize to distant parts of the body, the hallmark of deadly, aggressive cancer.

4 Oct 2011

New research uses Tilman model to study metastasis of prostate cells into bone

The invasion of a new species into an established ecosystem can be directly compared to the steps involved in cancer metastasis. New research published in BioMed Central's open access journal Theoretical Biology and Medical Modelling uses the Tilman model of competition between invasive species to study the metastasis of prostate cells into bone.

3 Oct 2011

Blueberry powder may control triple negative breast cancer

In several studies recently conducted at the Beckman Research Institute at the City of Hope, Duarte, CA researchers found that feeding blueberry powder to mice significantly reduced the growth and spread of triple negative breast cancer cells, a very aggressive form of cancer.

1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

PTK6 protein may play a different role in colon and breast cancer

A protein that regulates cell differentiation in normal tissue may play a different role in colon and breast cancer, activating proliferation of damaged cells, according to researchers at the University of Illinois at Chicago College of Medicine.

30 Sep 2011

Beta-blockers can prevent breast cancer metastasis and improve survival

Cancer Research UK scientists are investigating whether beta-blockers hold the key to preventing breast cancer spread and improving survival. Promising early results will be presented on the eve of breast cancer awareness month at the Royal Society of Medicine.

30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

Simple low-cost method for isolation and collection of fragile prostate cancer cells

At the Oct. 2-6 microTAS 2011 conference, the premier international event for reporting research in microfluidics, nanotechnology and detection technologies for life science and chemistry, University of Cincinnati researchers will present a simple, low-cost, method for separating and safely collecting concentrated volumes of fragile prostate cancer cells.

29 Sep 2011

Eating blueberries may inhibit breast cancer tumor growth

Eating blueberries may inhibit breast cancer tumor growth, according to a recent study by researchers at the City of Hope in Los Angeles that is published in the October 2011 issue of The Journal Of Nutrition and featured in the September issue of Food Nutrition & Science.

27 Sep 2011

Zoledronic acid may extend survival in older breast cancer patients

A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds.

27 Sep 2011

Zoledronic acid may benefit post-menopausal women with breast cancer

A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Zometa bone drug trial in post-menopausal women with breast cancer

Results from a latest large-scale clinical trial called Azure found that Novartis AG's bone drug Zometa extended survival in older breast cancer patients but failed to improve disease-free survival among younger women patients.

26 Sep 2011

First Radium-223 Chloride Phase III study in prostate cancer

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported today (Saturday) at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for its 2011 fiscal year, ended June 30, 2011.

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011